Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.

<h4>Background</h4>Moderate-to-severe atopic dermatitis (AD) often requires long-term management with systemic therapies.<h4>Objective</h4>Our objective was to report the safety and efficacy of dupilumab treatment up to 4 years in adults with moderate-to-severe AD and efficacy in a subgroup of patie... View More